Q-omics provides the consensus-scored MIR422A profile across patient tissues and cancer cell-line models. MIR422A expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR422A is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, MIR422A RNA expression shows 6,289 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LUSC, and STAD as cancer lineages where MIR422A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR422A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR422A survival associations across molecular data types. MIR422A RNA expression shows survival associations in the most cancer types (9), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR422A RNA expression–survival associations across cancer types. High MIR422A expression shows unfavorable associations in MESO, LIHC, DLBC, KIRC and LUSC, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR422A RNA expression.
This table summarizes MIR422A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR422A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR422A shows lower tumor expression in LUSC and higher tumor expression in UCEC. The LUSC box plot shows higher MIR422A RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p = .005).
This table shows molecular features associated with MIR422A in patient tissues and cancer cell lines. In patient samples, MIR422A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
